Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deflazacort vs Prednisolone in Acute-stage ABPA
NCT04227483Phase 3Active, not recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jan 2020
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of deflazacort in allergic bronchopulmonary aspergillosis (ABPA), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Weight gain at 2 months. Started Jan 2020; status: active, not recruiting.
02
Drugs
deflazacort
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT04227483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227483.